Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. The EC50 for this effect is 2-8 ng/mL.
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | Interferon lambda-2; IFN-lambda-2; Cytokine Zcyto20; Interleukin-28A (IL-28A) |
Accession | Q8IZJ0 |
Amino Acid Sequence | Val26-Val200 |
Expression System | E.coli |
Molecular Weight | 17-18 kDa (Reducing) |
Purity | >95% by SDS-PAGE and HPLC. |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | No Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, pH7.4 |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Reference | J Virol. 2010 Jun;84(11):5670-7. Epub 2010 Mar 24. |
Background
Interleukin-28A (IL-28A), also known as interferon lambda-2 (IFN-λ2), is a member of the type III interferon family. It is produced in response to viral infections and plays a critical role in the innate immune response. IL-28A exhibits antiviral activity by inducing the expression of interferon-stimulated genes (ISGs) and activating immune cells to inhibit viral replication and spread. IL-28A is primarily expressed by immune cells, such as dendritic cells and macrophages, and acts through the IFN-λ receptor complex to exert its antiviral effects. Due to its role in antiviral defense and immune regulation, IL-28A has garnered significant interest as a potential therapeutic target for viral infections, including hepatitis C and respiratory viruses.
Picture
Picture
Bioactivity
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
SEC-HPLC
>95% as determined by SEC-HPLC.
